|

APG-115 Clinical Trials

5 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Also known as: alrizomadlin

Pipeline

Phase 1: 2Phase 2: 1Phase 1/2: 2

Top Sponsors

  • Ascentage Pharma Group Inc.4
  • AeRang Kim1

Indications

  • Cancer5
  • Neurofibromatosis 1 (NF1)1
  • Atypical Neurofibroma1
  • Malignant Peripheral Nerve Sheath Tumor (MPNST)1
  • Non-Hodgkins Lymphoma1

Other3 trials

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Phase 1
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Phase 1
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Phase 1/2

Washington D.C., District of Columbia1 trial

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

Children's National Hospital

Phase 1/2

Houston, Texas1 trial

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

MD Anderson

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.